Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer’s Disease Therapy
ACS Nano · 30.01.2024 · 18 (4) · 3234-3250
DOI: 10.1021/acsnano.3c09715 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 12.01.2024. Verfasst von Ting Lei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Alzheimer Disease, Nanoparticles. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, Fundamental Research Funds for the Central Universities.
Themen: Demenz
Abstract (Originalsprache)
A brain-targeting nanodelivery system has been a hot topic and has undergone rapid progression. However, due to various obstacles such as the intestinal epithelial barrier (IEB) and the blood-brain barrier (BBB), few nanocarriers can achieve brain-targeting through oral administration. Herein, an intelligent oral brain-targeting nanoparticle (FTY@Man NP) constructed from a PLGA-PEG skeleton loaded with fingolimod (FTY) and externally modified with mannose was designed in combination with a glucose control strategy for the multitarget treatment of Alzheimer's disease (AD). The hydrophilic and electronegative properties of the nanoparticle facilitated its facile penetration through the mucus barrier, while the mannose ligand conferred IEB targeting abilities to the nanoparticle. Subsequently, glycemic control allowed the mannose-integrated nanoparticle to hitchhike the glucose transporter 1 (GLUT1) circulation across the BBB. Finally, the released FTY modulated the polarity of microglia from pro-inflammatory M1 to anti-inflammatory M2 and normalized the activated astrocyte, enhancing the clearance of toxic protein Amyloid-β (Aβ) while alleviating oxidative stress and neuroinflammation. Notably, both in vitro and in vivo results have consistently demonstrated that the oral administration of FTY@Man NP could effectively traverse the multiple barriers, thereby exerting significant therapeutic effects. This breakthrough holds the promise of realizing a highly effective orally administered treatment for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
ORCID-Profile: Huile Gao
Förderung
- Science and Technology Department of Sichuan Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Lei, T., Yang, Z., Jiang, C., Wang, X., Yang, W., Yang, X., Xie, R., Tong, F., Xia, X., Huang, Q., Du, Y., Huang, Y., & Gao, H. (2024). Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer’s Disease Therapy. ACS Nano, 18(4), 3234-3250. https://doi.org/10.1021/acsnano.3c09715
Vancouver
Lei T, Yang Z, Jiang C, Wang X, Yang W, Yang X, et al. Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer’s Disease Therapy. ACS Nano. 2024;18(4):3234-3250. doi:10.1021/acsnano.3c09715
BibTeX
@article{Lei2024,
author = {Lei, Ting and Yang, Zixiao and Jiang, Chaoqing and Wang, Xiaorong and Yang, Wenqin and Yang, Xiaotong and Xie, Rou and Tong, Fan and Xia, Xue and Huang, Qianqian and Du, Yufan and Huang, Yuan and Gao, Huile},
title = {Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer’s Disease Therapy},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {4},
pages = {3234--3250},
doi = {10.1021/acsnano.3c09715}
}
EUVIMED